# Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/early-clinical-trials-with-live-biotherapeutic-products-chemistry-manufacturing-and-control-information-guidance-for-industry/6962bf37-7cfd-4243-ac04-43748353cd63

> FDA guidance document: Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry. Issue date: June 30, 2016. Get complete insights and analysis.

---

## Details

- Title: Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2016-06-30
- Last Changed: 2021-07-22
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2010-D-0500">FDA-2010-D-0500</a>

## Related Documents

- [Validation of Procedures for Processing of Human Tissues Intended for Transplantation:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/validation-of-procedures-for-processing-of-human-tissues-intended-for-transplantation-guidance-for-industry/098dfce7-8124-4658-98c8-d92a922f6766)
- [Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/determining-donor-eligibility-for-autologous-donors-of-blood-and-blood-components-intended-solely-for-autologous-use-compliance-policy-guidance-for-industry/66ca6a85-aebe-4b20-a0ba-d0f7e4e393d3)
- [Biological Product Deviation Reporting for Blood and Plasma Establishments:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/biological-product-deviation-reporting-for-blood-and-plasma-establishments-guidance-for-industry/6c58653c-8367-4da8-9b28-4e92356ee9c7)